SITE014-0108

SITE014 (NLD) › SITE014-0108

SITE014-0108

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-01-09

completed

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 103); relationship: NOT RELATED

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-11 (study day 55); relationship: NOT RELATED

mild assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-07 (study day 20); relationship: NOT RELATED

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 12); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.